Efficacy and Safety Profile of Subcutaneous Semaglutide for Weight Management in AdultsSemaglutide helps people with obesity lose significant body weight

This meta-analysis evaluates the clinical utility of subcutaneous semaglutide as a pharmacological intervention for weight management in adults. The study specifically targeted individuals presenting with overweight or obesity who do not have type 2 diabetes mellitus. By synthesizing data from multiple randomized controlled trials, the analysis provides a robust look at both primary efficacy outcomes and secondary safety metrics to inform clinical decision-making.

The primary endpoint of the meta-analysis was the percentage change in body weight from baseline. The results indicate that semaglutide produced a statistically significant reduction in body weight compared to placebo. Specifically, patients receiving semaglutide achieved an average weight loss of 11.85% (95% CI: -12.81 to -10.90; P <.00001). This substantial reduction underscores the potency of GLP-1 receptor agonists in managing obesity independently of glycemic status.

In addition to weight loss, the study monitored several secondary outcomes related to patient experience and safety. Gastrointestinal adverse events were significantly more frequent in the semaglutide cohort compared to those receiving placebo. These specific events included nausea, vomiting, diarrhea, and constipation. While these side effects are common with GLP-1 agonists, they represent a significant factor in patient adherence and overall treatment satisfaction.

Regarding severe safety concerns, the data indicated that serious adverse events such as acute pancreatitis and cholelithiasis were uncommon. However, there was a notable difference in treatment persistence. The rate of treatment discontinuation due to adverse events was significantly higher in the semaglutide group (RR 2.62, 95% CI: 1.70-4.03; P =.001). This suggests that while the drug is effective for weight loss, its tolerability profile requires careful patient selection and counseling.

Clinicians should consider semaglutide as a viable option for patients seeking significant weight reduction. The evidence supports its efficacy in achieving double-digit percentage weight loss. However, practitioners must weigh these benefits against the higher likelihood of gastrointestinal distress and the potential for early treatment cessation. Patient education regarding expected side effects is crucial for improving long-term compliance.

Despite the strong results, the meta-analysis highlights certain limitations that should guide clinical interpretation. Because this was a synthesis of existing trials, the data does not provide definitive evidence on the durability of weight loss over several years or the long-term safety profile beyond the study windows. Further longitudinal randomized trials are necessary to establish these parameters before making long-term projections for patients.